Clinical Neuroscience And NeuropathologyPostmortem serotoninergic correlates of cognitive decline in Alzheimer's diseaseLai, Mitchell K. P.1 2; Tsang, Shirley W. Y.2; Francis, Paul T.3; Keene, Janet4; Hope, Tony4 6; Esiri, Margaret M.5; Spence, Ian1; Chen, Christopher P. L.-H.2 CA Author Information 1Department of Pharmacology, University of Sydney, NSW 2006, Australia 2Department of Neurology, Block 6, Level 6, Room A5, Singapore General Hospital, Outram Road, Singapore 169608 3Dementia Research Laboratory, Centre for Neuroscience Research, GKT School of Biomedical Science, King's College London SE1 1UL 4Department of Psychiatry 5Department of Neuropathology 6Department of Ethox, Institute of Health Sciences, Oxford University, Oxford, UK CACorresponding Author Received 4 April 2002 accepted 30 April 2002 Neuroreport 13(9):p 1175-1178, July 2, 2002. Buy Abstract Serotonin1A receptor density and serotonin concentration were measured in the postmortem neocortex of 17 AD patients who had been prospectively assessed every four months with the Mini-Mental State Examination (MMSE) for a mean of 2.6 years till death. In the frontal cortex, serotonin levels correlated negatively with the annual rate of MMSE decline, while serotonin1A receptor density was positively correlated with the rate of MMSE decline. Our study suggests that reduced serotonin levels and increased serotonin1A receptor density are markers for accelerated cognitive decline in AD, and provides support for the use of serotonin1A antagonists in the treatment of AD. © 2002 Lippincott Williams & Wilkins, Inc.